Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Q&A: Robyn Guymer highlights risk factors of intermediate AMD | Ophthalmology Times
Photo of Robyn Guymer at EURETINA 2025 in Paris, France Professor Robyn Guymer from the University of Melbourne discussed intermediate age-related macular degeneration (AMD) at the 2025 EURETINA meeting. She explored risk factors for disease progression, focusing on optical coherence…
iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy | Ophthalmology Times
iVeena Delivery Systems has been awarded a $2 million phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will help to advance development of novel topical eye…
Christine Kay, MD, on the 152-week results of the RESTORE study for retinitis pigmentosa | Ophthalmology Times
Christine Kay, MD, a vitreoretinal surgeon and IRD specialist from Gainesville, Florida, presented the results of the RESTORE trial for MCO-010 optogenetic therapy for retinitis pigmentosa. The trial was a 152-week analysis of a novel gene therapy targeting bipolar cells.…
Horus Pharma selected as additional commercialization partner for aflibercept biosimilar in Europe | Ophthalmology Times
(Image credit: AdobeStock) Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon’s Eylea1 biosimilar FYB203 (aflibercept), issued an additional semi-exclusive license agreement with Horus Pharma for the commercialization of FYB203/Baiama 2 in selected European countries.1…
David Almeida, MD, MBA, PhD, advances ophthalmic training with near real surgical specimens | Ophthalmology Times
David Almeida, MD, MBA, PhD, highlights near real surgical systems (NRSS), providing ophthalmologists with anatomically accurate models that replicate real surgical scenarios for training, research, and device development. (Image credit: AdobeStock/Iurii) A vitreoretinal surgeon and clinician-scientist with Erie Retina Research…
Kalaris enrolling phase 1b/2 study of TH103 for nAMD | Ophthalmology Times
(Image credit: ©kwanchaift/AdobeStock) Kalaris Therapeutics announced the company is currently enrolling a phase 1b/2 multiple ascending dose (MAD) study of TH103 for the treatment of neovascular age-related macular degeneration (nAMD).1 “The phase 1b/2 study represents an important milestone in advancing…
Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye
To learn more about or to register for EyeCon 2025, click here. Set against the backdrop of a scenic Florida coastline and a growing emphasis on cross-specialty collaboration in eye care, the Ophthalmology Times and Optometry Times EyeCon® 2025 conference is…
Effects of calcium channel blockers on visual field progression in glaucoma patients
(Image credit: AdobeStock) Researchers from UK and Italian institutions investigated the association between the effects of calcium channel blockers and the rate of visual field (VF) progression in patients with glaucoma. First author Giovanni Montesano, MD, PhD, and colleagues reported…
Sandoz and Regeneron reach agreement over biosimilar dispute
(Image Credit: AdobeStock) Sandoz and Regeneron Pharmaceuticals have announced an agreement settling all patent disputes between the 2 companies relating to the US Food and Drug Administration (FDA)-approved Sandoz aflibercept biosimilar. Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv)…
UnitedHealthcare updates Glaucoma Surgical Treatments policy
(Image Credit: AdobeStock/gguy) UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts…